Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaPhilip L. McCarthy, Charles Linker, Luis Isola et al.|New England Journal of Medicine|2012Cited by 1.1k
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosisRaymond L. Comenzo, Giampaolo Merlini, Donna Reece et al.|Leukemia|2012Cited by 383
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionMorie A. Gertz, Michaela Liedtke, Heather Landau et al.|Journal of Clinical Oncology|2016Cited by 206
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaOla Landgren, Neha Korde, Malin Hultcrantz et al.|JAMA Oncology|2021Cited by 119
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical TrialSham Mailankody, Eric L. Smith, Arnab Ghosh et al.|Blood|2018Cited by 100